Slide 1: Phase 3 Interim Analysis Investor Webinar
@w Dimerix (ASX:DXB) 12 March 2024 Phase 3 Interim Analysis Investor Webinar For personal use only Developing new therapies to treat inflammatory causes of kidney and respiratory disease with unmet clinical needs ACTIONS FSGS CLINICAL STUDY Authorised for lodgement by the Board of the Company
Slide 2: Forward looking statements
Forward looking stateme SShis presentation includes forward-looking statements that are subject to” “Clisks and uncertainties. Such statements involve known and unknowr sks and important factors that may cause the actual result Qerrormance or achievements of Dimerix to be materially different fre =t
Slide 3: Lead Drug Candidate – DMX-200 in FSGS
Lead Drug Candidate – DMX-200 in focal segmental glomerulosclerosis (FSGS) For personal use only
Slide 4: What is FSGS? Why are kidneys important? Why is proteinuria important?
For personal use only What is FSGS? Why are kidneys important? Why is proteinuria important?
Slide 5: FSGS causes and prognosis
FSGS causes and prognosis Focal segmental glomerulosclerosis (FSGS) is one of the most common forms of acquired glomerular disease leading to end stage kidney disease (ESKD), requiring dialysis or transplant = Cc > Caused by a variety of conditions - primary FSGS, genetic FSGS, FSGS of unknown cause
Slide 6: Progression of FSGS kidney disease
Progression of FSGS kidney disease For personal use only Existing blood pressure medication targets Step 1: angiotensin receptor blocker (ARB) lowers blood pressure N Less kidney cells cause further hyperfiltration and inflammation Kidney vessels have to work harderunder highypressure 1 DMX-200 inte
Slide 7: Phase 3 Clinical Trial
PHASE 3 CLINICAL TRIAL For personal use only @ Dimerix
Slide 8: ACTION3 Part 1 interim analysis successful
OQ ACTICIN3 Part 1 interim analysis successful FSGS CLINICAL STUDY ACTION3 Phase 3 trial successfully passes first interim analysis (using a statistical measure’) based on proteinuria efficacy endpoint? hat does this interim analysis mean? An interim analysis incorporating a futility assessment is d
Slide 9: ACTION3 Part 1 analysis interpretation
OQ ACTICIN3 Part 1 analysis interpretation FSGS CLINICAL STUDY ACTIONS Phase 3 trial successfully passes first interim analysis using proteinuria efficacy endpoint! This means that: o DMX-200 is currently performing better than placebo in reducing proteinuria in patients with FSGS (using a statistic
Slide 10: ACTION3 Part 1 analysis observations
Oxy ACTIANS Part 1 analysis observations FSGS CLINICAL STUDY For personal-use-only “It is very pleasing to see that the Phase 3 clinical trial of DMX-200 was successful in the pre-specified interim futility analysis for efficacy in the first 72 patients. The positive signal suggests that treatment w
Slide 11: Background Phase 3 Trial Timeline
For personal use only Background Phase 3 Trial Timeline • • •
Slide 12: For personal use only
For personal use only • • • • • • • • •
Slide 13: FSGS Market Opportunity
FSGS MARKET OPPORTUNITY For personal use only @ Dimerix
Slide 14: Potential FSGS market size
Potential FSGS market size Estimated 7MM (+China) No approved therapies for F @ diagnosed patients (2022)'4 DMX-200 is the only therapy in phase 3 development O Muilti-billion dollar market potential O >303,000 patients A na Example pricing for other rare kidney disease drugs : * in the US (i.e. Fil
Slide 15: Dimerix - strategic partners in nephrology
wo Dimerix - strategic partners in nephrology Dimerix has received a > significant amount of partnering Preference is to work with _— interest from pharma experienced, capable partners Cc companies globally 2) + Received multiple non-binding + Partners with regulatory, sales @)_ term sheets for glob
Slide 16: Lead Drug Candidate, FSGS, Market Opportunity, Commercial Validation, Upcoming Milestones
Lead Drug Candidate For personal use only • • FSGS • • • Market Opportunity • • • Commercial Validation • • • Upcoming Milestones • •
Slide 17: Capital Raising Details
CAPITAL RAISING DETAILS For personal use only @ Dimerix
Slide 18: For personal use only
For personal use only • • • • • • • •
Slide 19: Use of funds
Use of funds Zig forma capital structu | Intended use of funds A$ Million OOrdinary shares on issue prior to the Capital Raise 454,741,433 Clinical studies, including: + — ACTION3 Phase 3 clinical trial in patients with FSGS QWupndiluted market capitalisation pre-Capital Raising! $136.4M + Preparati
Slide 20: Offer timetable
Offer timetable* Trading halt Placement announced, trading halt lifted Allotment and trading of New Shares under the Placement For personal use only Monday, 11 March 2024 Tuesday, 12 March 2024 Wednesday, 20 March 2024 @ Dimerix “The timetable above Is indicative only and Is subject to change, inclu
Slide 21: For personal use only
For personal use only • • • • • • • • • •
Slide 22: Corporate overview
Corporate overview For personal use only days* Ticker Symbol ASX: DXB Proforma Cash Balance (Dec23)' “A$34.8 million Market Capitalisation “A$136 million Share price ~A$0.30 Total ordinary shares on issue 454,741,433 Average daily liquidity for past 30 5.88 million HARE PRICE 038 50 oa ions) 025 30
Slide 23: For personal use only
For personal use only A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases. WELL POSITIONED TO DELIVER OUR STRATEGIC PLAN ESG Statement SCAN ME Dimerix HQ 425 Sm